TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25915510

Group type: EXPERIMENTAL
Intervention: Stent implantation into RCA
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Stent implantation into SVG-RCA
Number of subjects: 14
Study: 25915616

Group type: COMPARATOR
Intervention: IPTp-MQ (2 doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: IPTp-MQ (3 doses) added to CTXp
Number of subjects: 0

Group type: COMPARATOR
Intervention: CTXp alone
Number of subjects: 0
Study: 25915689

Group type: EXPERIMENTAL
Intervention: Coping-motivated marijuana use
Number of subjects: 288

Group type: COMPARATOR
Intervention: Enhancement or social reasons for marijuana use
Number of subjects: 288
Study: 25915780

Group type: EXPERIMENTAL
Intervention: IMMU-132 (17.5 mg/kg; twice weekly × 4 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IMMU-132 (dosing schemes: every other week, weekly, or twice weekly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (nonspecific control)
Number of subjects: 0
Study: 25916280

Group type: EXPERIMENTAL
Intervention: 3-weeks ECG Holter monitoring
Number of subjects: 105

Group type: COMPARATOR
Intervention: 24-hour ECG Holter monitoring
Number of subjects: 105
Study: 25916814

Group type: COMPARATOR
Intervention: Single ATP burst (Group 1)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Multiple ATP bursts (Group 2)
Number of subjects: 154
Study: 25916910

Group type: EXPERIMENTAL
Intervention: Salivary composition in normal-weight subjects
Number of subjects: 18

Group type: COMPARATOR
Intervention: Salivary composition in obese subjects
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Postprandial lipid metabolism
Number of subjects: 18
Study: 25917561

Group type: EXPERIMENTAL
Intervention: Clopidogrel (600 mg)
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg)
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg)
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: New-generation P2Y₁₂ receptor antagonists
Number of subjects: 589
Study: 25917683

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 8 weeks
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Greater DLPFC activity during CPT
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: DLPFC activity
Number of subjects: 98
Study: 25918250

Group type: EXPERIMENTAL
Intervention: Cetuximab (400mg/m², then 250mg/m²) and trastuzumab (3.0 or 4.0mg/kg, then 1.5 or 2.0mg/kg weekly)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cetuximab and trastuzumab
Number of subjects: 49
Study: 25918553

Group type: EXPERIMENTAL
Intervention: Metatranscriptome analysis of subgingival biofilms from progressing sites
Number of subjects: 743000000

Group type: COMPARATOR
Intervention: Metatranscriptome analysis of subgingival biofilms from stable sites
Number of subjects: 743000000

Group type: EXPERIMENTAL
Intervention: Overall microbial community analysis
Number of subjects: 743000000
Study: 25918556

Group type: EXPERIMENTAL
Intervention: CAD106 (150μg, subcutaneous/intramuscular injections)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 25918559

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of sirolimus
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of sirolimus
Number of subjects: 30
Study: 25919461

Group type: EXPERIMENTAL
Intervention: KRN23 (anti-FGF23 antibody) injected subcutaneously every 28 days, dosage 0.05-0.6 mg/kg during dose-escalation and 0.1-1 mg/kg during extension
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: KRN23 (anti-FGF23 antibody)
Number of subjects: 28
Study: 25921059

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg by mouth daily
Number of subjects: 16
Study: 25921689

Group type: EXPERIMENTAL
Intervention: TDF 150 mg once daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: TDF 300 mg every 48 hours
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TDF 150 mg once daily and TDF 300 mg every 48 hours
Number of subjects: 40
Study: 25922544

Group type: EXPERIMENTAL
Intervention: Spontaneous Breathing Trial (SBT)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Fluid balance in the 48 h before SBT
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Positive fluid balance in COPD subgroup
Number of subjects: 250
Study: 25923040

Group type: EXPERIMENTAL
Intervention: Postoperative copeptin levels measured daily until discharge
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Copeptin <2.5 pmol/L on postoperative day 1
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Copeptin >30 pmol/L on postoperative day 1
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis of postoperative copeptin concentrations
Number of subjects: 205
Study: 25923090

Group type: EXPERIMENTAL
Intervention: Anti-TPO positive group (32 patients, 43.2%)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Anti-TPO negative group (42 patients, 56.8%)
Number of subjects: 74
Study: 25923426

Group type: EXPERIMENTAL
Intervention: Bacterial culture and analysis
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Detection of respiratory viruses
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Nonsusceptibility testing for Streptococcus pneumoniae
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Concurrent detection of pathogens
Number of subjects: 260
Study: 25923549

Group type: EXPERIMENTAL
Intervention: AZD9291 (20 to 240 mg once daily)
Number of subjects: 253
Study: 25923603

Group type: EXPERIMENTAL
Intervention: Whole-protein supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Essential amino-acid supplements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: β-hydroxyl β-methylbutyrate (HMB)
Number of subjects: 0
Study: 25923731

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 27
Study: 25924874

Group type: EXPERIMENTAL
Intervention: PRKACA amplification (triplication)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: PRKACA amplification (duplication)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Constitutional chromosomal PRKACA gene amplification
Number of subjects: 5
Study: 25924934

Group type: EXPERIMENTAL
Intervention: Nasal CPAP mask at pressures of 5, 10, and 15 cm of H2O
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oronasal CPAP mask at pressures of 5, 10, and 15 cm of H2O
Number of subjects: 10
Study: 25924986

Group type: EXPERIMENTAL
Intervention: Index offspring (adolescent offspring of mothers with type 1 diabetes)
Number of subjects: 581

Group type: COMPARATOR
Intervention: Control offspring (non-diabetic mothers)
Number of subjects: 581
Study: 25924987

Group type: COMPARATOR
Intervention: No weight change
Number of subjects: 3485

Group type: EXPERIMENTAL
Intervention: Minor weight reduction
Number of subjects: 3485

Group type: EXPERIMENTAL
Intervention: Medium weight reduction
Number of subjects: 3485

Group type: EXPERIMENTAL
Intervention: Major weight reduction
Number of subjects: 3485
Study: 25924990

Group type: COMPARATOR
Intervention: Salmeterol (50 μg) administered after placebo; 4 weeks of treatment with salmeterol 50 μg twice daily.
Number of subjects: 32
Study: 25924991

Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg in combination with paclitaxel (PTX) and carboplatin (CBDCA)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg in combination with paclitaxel (PTX) and carboplatin (CBDCA)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg and 10 mg/kg in combination with paclitaxel (PTX) and carboplatin (CBDCA)
Number of subjects: 15
Study: 25925007

Group type: EXPERIMENTAL
Intervention: Participatory, local community approach
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Information communication technology (ICT) approach
Number of subjects: 124
Study: 25925351

Group type: EXPERIMENTAL
Intervention: PCOS embryos
Number of subjects: 43

Group type: COMPARATOR
Intervention: Non-PCOS embryos
Number of subjects: 43
Study: 25925407

Group type: EXPERIMENTAL
Intervention: Community-based intervention package (promotion of antenatal care, adequate nutrition, skilled delivery, healthy newborn care practices)
Number of subjects: 3200

Group type: EXPERIMENTAL
Intervention: Community-based intervention package
Number of subjects: 3200
Study: 25925619

Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin (0.1-2.4 mg/kg every 21 days) as a single agent
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin combined with rituximab (375 mg/m2)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin (1.0 mg/kg) in CLL
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin (2.4 mg/kg) in NHL
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Rituximab combination cohort
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 95
Study: 25925673

Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg/day) for two weeks prior to surgery
Number of subjects: 50
Study: 25925749

Group type: EXPERIMENTAL
Intervention: Capecitabine plus irinotecan (XELIRI) regimen with bevacizumab
Number of subjects: 77
Study: 25926311

Group type: EXPERIMENTAL
Intervention: Non-invasive cardiac output monitoring device (NICOM)
Number of subjects: 29
Study: 25926352

Group type: EXPERIMENTAL
Intervention: Preoperative capecitabine (825 mg/m² b.i.d. Monday-Friday), oxaliplatin (50 mg/m² weekly), bevacizumab (5 mg/kg on days 1, 15, and 29), and radiation therapy (50.4 Gy) followed by surgery and postoperative FOLFOX plus bevacizumab (5 mg/kg) every 2 weeks for 12 cycles.
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Preoperative therapy (capecitabine, oxaliplatin, bevacizumab, and RT) followed by surgery and postoperative FOLFOX plus bevacizumab.
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Preoperative therapy followed by surgery and postoperative FOLFOX plus bevacizumab.
Number of subjects: 53
Study: 25926600

Group type: EXPERIMENTAL
Intervention: Prophylactic doses of danaparoid or fondaparinux for participants with low 4Ts score or intermediate 4Ts score plus negative PF4/H-PaGIA result.
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Therapeutic doses of nonheparin anticoagulants for all others.
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Negative PF4/H-PaGIA result.
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Positive PF4/H-PaGIA result.
Number of subjects: 526
Study: 25926790

Group type: EXPERIMENTAL
Intervention: Non-action video game training (20 sessions, 1 hour each)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (attended meetings with research team, no training)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Non-action video game training
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2
Study: 25926858

Group type: EXPERIMENTAL
Intervention: Darunavir/cobicistat 800/150 mg once daily
Number of subjects: 313
Study: 25927357

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) using the iPro(®)2 system
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Overall assessment of glycemic control using CGM
Number of subjects: 84
Study: 25927460

Group type: EXPERIMENTAL
Intervention: Patient Blood Management (PBM) program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-implementation cohort
Number of subjects: 0
Study: 25927526

Group type: EXPERIMENTAL
Intervention: PCR testing in HIV-positive cases
Number of subjects: 525

Group type: COMPARATOR
Intervention: PCR testing in HIV-negative well-controls
Number of subjects: 525

Group type: COMPARATOR
Intervention: PCR testing in HIV-positive well-controls
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Microscopy testing in HIV-positive cases
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Culture testing in HIV-positive cases
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Culture testing in HIV-negative cases
Number of subjects: 525

Group type: COMPARATOR
Intervention: Culture testing in HIV-negative specimens
Number of subjects: 525

Group type: COMPARATOR
Intervention: Culture testing in HIV-positive specimens
Number of subjects: 525
Study: 25927528

Group type: EXPERIMENTAL
Intervention: Relaxation Response Mind-Body Intervention (RR-MBI)
Number of subjects: 48
Study: 25927615

Group type: EXPERIMENTAL
Intervention: Accelerometer monitoring using ActiGraph GT3X+ for 7 days with a 24-hr waist worn protocol.
Number of subjects: 7806
Study: 25927915

Group type: EXPERIMENTAL
Intervention: Aspergillus lateral-flow device (LFD) test for BAL IPA detection
Number of subjects: 133

Group type: COMPARATOR
Intervention: Fungal BAL culture
Number of subjects: 133
Study: 25927980

Group type: EXPERIMENTAL
Intervention: Emergency Medical Services (EMS) treatment for OHCA
Number of subjects: 0
Study: 25928189

Group type: EXPERIMENTAL
Intervention: Bilateral Bispectral Index (BIS)-monitoring during pre-, intra- and postoperative period
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Bilateral BIS monitoring
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Burst Suppression Ratio (BSR)
Number of subjects: 81
Study: 25928811

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (1,000 mg iron)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose
Number of subjects: 30
Study: 25929250

Group type: EXPERIMENTAL
Intervention: Nicoboxil/nonivamide ointment
Number of subjects: 805

Group type: EXPERIMENTAL
Intervention: Nicoboxil ointment
Number of subjects: 805

Group type: EXPERIMENTAL
Intervention: Nonivamide ointment
Number of subjects: 805

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 805
Study: 25929276

Group type: EXPERIMENTAL
Intervention: Peripapillary retinal nerve fiber layer (RNFL) measurement
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Normalized normal appearing white matter volume
Number of subjects: 43
Study: 25929582

Group type: EXPERIMENTAL
Intervention: Axitinib combined with cisplatin/gemcitabine (starting dose 5 mg bid, titrated to 2-10 mg bid; cisplatin 80 mg/m2 i.v. every 3 weeks; gemcitabine 1,250 mg/m2 i.v. on days 1 and 8 of each 3-week cycle)
Number of subjects: 38
Study: 25929664

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 531
Study: 25929739

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg b.i.d.
Number of subjects: 293

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293
Study: 25929922

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted darunavir monotherapy (mtDRV/rtv)
Number of subjects: 71
Study: 25930082

Group type: EXPERIMENTAL
Intervention: Preoperative MENG recordings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative MENG recordings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraoperative recordings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative MENG data
Number of subjects: 0
Study: 25931518

Group type: EXPERIMENTAL
Intervention: Dinaciclib (20 mg/kg, i.p., three times a week) and MK-2206 (60 mg/kg, orally, three times a week)
Number of subjects: 8
Study: 25932660

Group type: EXPERIMENTAL
Intervention: sRAGE levels in plasma and bronchoalveolar fluid of acid-injured mice
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: sRAGE levels in plasma of patients with ARDS
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: sRAGE levels over time in mice
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: sRAGE levels and lung injury severity
Number of subjects: 30
Study: 25932696

Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 94

Group type: COMPARATOR
Intervention: Formula milk
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Younger gestational age at birth
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Presence of medical complications (neurological risk, bronchopulmonary dysplasia, necrotizing enterocolitis, patent ductus arteriosus)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Gastroesophageal reflux disease
Number of subjects: 94
Study: 25932797

Group type: EXPERIMENTAL
Intervention: Sleep restriction (4 hours of sleep)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Recovery (8 hours of sleep)
Number of subjects: 12
Study: 25933168

Group type: EXPERIMENTAL
Intervention: CPS-immunization
Number of subjects: 16
Study: 25933809

Group type: EXPERIMENTAL
Intervention: 5 years of imaging and CEA follow-up
Number of subjects: 0
Study: 25933833

Group type: EXPERIMENTAL
Intervention: Ilorasertib (540 mg once weekly and 480 mg twice weekly)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Ilorasertib (oral)
Number of subjects: 52
Study: 25934187

Group type: COMPARATOR
Intervention: Presence of mtDNA polymorphisms at positions 16519 and 3010 in individuals with functional syndromes.
Number of subjects: 0
Study: 25934475

Group type: EXPERIMENTAL
Intervention: Combination DFX-deferoxamine (DFO)
Number of subjects: 60
Study: 25934759

Group type: EXPERIMENTAL
Intervention: Peroral endoscopic myotomy (POEM)
Number of subjects: 80
Study: 25935493

Group type: EXPERIMENTAL
Intervention: Spent culture media (SCM) from embryos of obese women (n = 16)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Spent culture media (SCM) from embryos of normoweight women (n = 12)
Number of subjects: 28
Study: 25935574

Group type: EXPERIMENTAL
Intervention: CDEIS
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SES-CD
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: GELS
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CDEIS and GELS
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SES-CD and GELS
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CDEIS and SES-CD
Number of subjects: 50
Study: 25935582

Group type: EXPERIMENTAL
Intervention: Tamoxifen (5 years)
Number of subjects: 4861

Group type: EXPERIMENTAL
Intervention: Letrozole (5 years)
Number of subjects: 4861
Study: 25935794

Group type: EXPERIMENTAL
Intervention: High-dose clarithromycin (2 g/day, oral, days 1-14, every 21 days)
Number of subjects: 23
Study: 25936321

Group type: EXPERIMENTAL
Intervention: Apheresis treatment with atorvastatin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Atorvastatin monotherapy
Number of subjects: 30
Study: 25936396

Group type: EXPERIMENTAL
Intervention: Change in hippocampal volume (measured by fit slope)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Change in hippocampal volume (measured by percentage change)
Number of subjects: 27
Study: 25936597

Group type: EXPERIMENTAL
Intervention: Androgen suppression for 12 months and radiation therapy (25 Gy to pelvic nodes and 40 Gy to prostate, 1 fraction per week over 5 weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Androgen suppression for 12 months and radiation therapy
Number of subjects: 16
Study: 25936984

Group type: EXPERIMENTAL
Intervention: Retinal gene therapy
Number of subjects: 3
Study: 25937263

Group type: EXPERIMENTAL
Intervention: High dose alkylating chemotherapy (HDAC) based on BRCA1-like testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BRCA1-like testing
Number of subjects: 0
Study: 25937426

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160mg/day
Number of subjects: 67
Study: 25937431

Group type: EXPERIMENTAL
Intervention: Dacomitinib (45 mg) administered via gastrostomy feeding tube (GT) in fasting state and supine position.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Dacomitinib via GT
Number of subjects: 6
Study: 25937529

Group type: EXPERIMENTAL
Intervention: Therapeutic trial enrollment
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Trial availability
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Factors associated with trial ineligibility
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Enrollment odds for non-White patients
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Enrollment odds for patients of Black physicians
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Belief that trial may help
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Concern about care if not on trial
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Pressure to enroll
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Caregiving without pay
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Physician belief about standard therapy
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Physician belief about trial time consumption
Number of subjects: 781
Study: 25937606

Group type: EXPERIMENTAL
Intervention: Endurant stent graft in REG anatomy
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Endurant stent graft in INT anatomy
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Endurant stent graft in CHA anatomy
Number of subjects: 1218
Study: 25937868

Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg/d in 6-wk cycles (4 wk on treatment followed by 2 wk off treatment)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg/d
Number of subjects: 3
Study: 25938001

Group type: EXPERIMENTAL
Intervention: Temsirolimus 175/75 mg
Number of subjects: 162

Group type: COMPARATOR
Intervention: INV (investigator's choice of therapy)
Number of subjects: 162
Study: 25938124

Group type: EXPERIMENTAL
Intervention: 1-session HIV education
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: 3-session HIV education
Number of subjects: 148

Group type: COMPARATOR
Intervention: No HIV education (control group)
Number of subjects: 148
Study: 25938292

Group type: EXPERIMENTAL
Intervention: Health-related quality of life measured by SGRQ score
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Dyspnea
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Chronic bronchitis
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Wheezing
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Number of exacerbations in the year before inclusion
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: 6-min walking distance
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: FEV1 (% predicted)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: DLCO (% predicted)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: GOLD 2006 classification
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: GOLD 2011 classification
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: BODE index
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Multivariate analysis model including age, chronic bronchitis, dyspnea (MRC scale), diffusing lung capacity and 6-min walking distance
Number of subjects: 273
Study: 25938519

Group type: EXPERIMENTAL
Intervention: hNSCs differentiated on 3D scaffolds
Number of subjects: 0
Study: 25938638

Group type: EXPERIMENTAL
Intervention: Gene therapy with rAAV2/2 RPE65 vector
Number of subjects: 12